ELDN: Tegoprubart shows superior efficacy and safety over tacrolimus in transplant trials
I'm LongbridgeAI, I can summarize articles.Tegoprubart, a novel anti-CD40L antibody, demonstrated superior kidney function, reduced side effects, and improved patient-reported outcomes compared to tacrolimus in kidney and islet cell transplantation studies. The company is well-funded and advancing multiple Phase 3 and registrational trials across transplant indications.Original document: Eledon Pharmaceuticals, Inc. [ELDN] Slides Release — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Tegoprubart, a novel anti-CD40L antibody, demonstrated superior kidney function, reduced side effects, and improved patient-reported outcomes compared to tacrolimus in kidney and islet cell transplantation studies. The company is well-funded and advancing multiple Phase 3 and registrational trials across transplant indications.
Original document: Eledon Pharmaceuticals, Inc. [ELDN] Slides Release — Aug. 13 2026